

SUPPLEMENTARY MATERIAL

Supplementary Table 1. Genital coinfections with <i>Mycoplasma genitalium</i> ^{ab}						
	MG negative n= 1220 (%, 95% CI)		MG positive n=83 (%, 95% CI)		Adjusted Odds Ratio (95% CI) ^c	p-value ^d
<i>Chlamydia trachomatis</i>^e						
Negative	1118	(92, 91–94)	75	(90, 82–96)	1	
Positive	92	(8, 6–9)	8	(10, 4–18)	1.28	(0.60–2.74) 0.525
<i>Neisseria gonorrhoeae</i>^f						
Negative	1199	(99, 98–100)	82	(99, 93–100)	1	
Positive	11	(1, 0–2)	1	(1, 0–7)	1.27	(0.16–10.01) 0.818
Bacterial vaginosis^g						
Negative	813	(70, 67–73)	51	(64, 52–74)	1	
Positive	349	(30, 27–33)	29	(36, 26–48)	1.29	(0.80–2.07) 0.295
Vulvovaginal candidiasis^h						
Negative	918	(77, 74–79)	61	(74, 64–83)	1	
Positive	281	(23, 21–26)	21	(26, 17–36)	1.12	(0.67–1.88) 0.658

Abbreviations: MG=*Mycoplasma genitalium*, n=number, CI=confidence interval

^aWomen with an unassessable MG result (n=15) were excluded from the analysis

^b*Trichomonas vaginalis* is extremely uncommon at Melbourne Sexual Health Centre and present in <1% of attendees. 41 women with MG were assessed for *T. vaginalis* and only 1 (2%) was positive for *T. vaginalis*.

^cAdjusted for number of male sexual partners in the last three months as a risk factor.

^dp-value calculated using logistic regression

^e*C. trachomatis* result was unassessable in 9 women and not tested for in 1 woman.

^f*N. gonorrhoeae* result was unassessable in 8 women and not tested for in 2 women.

^gBacterial vaginosis was not assessed in 61 women.

^hVulvovaginal candidiasis was not assessed in 22 women.

Supplementary Table 2. Associations between *Chlamydia trachomatis* and demographics, past sexual practices and self-reported symptoms in the prior week^a

	CT negative N=1133 median (range) or n (%), 95% CI)	CT positive N=92 [median (range) or n (%), 95% CI]	Adjusted Odds Ratio (95% CI) ^b	p- value ^c
Median age	26 (23-29)	24 (22-29)	0.97 (0.92–1.01)	0.123
Median number of male partners in past 12m	4 (2-6)	4 (3-6)	1.02 (0.98–1.06)	0.341
Condom use in past 12m^d				
Always	82 (7, 6-9)	3 (3, 1-9)	1	
Not Always	1032 (93, 91-94)	88 (97, 91-99)	2.90 (0.69–12.09)	0.144
STI in the past 6m^{de}				
No	966 (87, 85-89)	77 (87, 78-93)	1	
Yes	146 (13, 11-15)	12 (13, 7-22)	0.65 (0.29-1.45)	0.295
<u>Self-reported symptoms (in the week prior to recruitment)</u>				
Abdominal Pain				
No	967 (86, 84-88)	79 (86, 77-92)	1	
Yes	161 (14, 12-16)	13 (14, 8-23)	0.86 (0.44-1.66)	0.647
Missing	5	0		
Dyspareunia				
Women with VVC				
No	256 (93, 89-96)	8 (73, 39-94)	1	
Yes	20 (7, 4-11)	3 (27, 6-61)	8.66 (1.90-39.54)	0.005
Women without VVC				
No	741 (90, 87-91)	71 (93, 85-98)	1	
Yes	87 (10, 9-13)	5 (7, 2-15)	0.48 (0.17-1.35)	0.164
Vaginal discharge				
No	755 (67, 64-70)	48 (53, 43-64)	1	
Yes	369 (33, 30-36)	42 (47, 36-57)	2.12 (1.32-3.42)	0.002
Missing	9	2		
Abnormal vaginal odour^f				
No	859 (76, 74-79)	65 (71, 61-80)	1	
Yes	264 (24, 21-26)	26 (29, 20-39)	1.36 (0.80-2.32)	0.257
Missing	10	1		
Vaginal itch				
No	886 (79, 76-81)	77 (85, 76-91)	1	
Yes	241 (21, 19-24)	14 (15, 9-24)	0.74 (0.37-1.48)	0.399
Missing	6	1		
Post-coital bleeding				
No	1033 (92, 90-94)	81 (89, 81-95)	1	
Yes	89 (8, 6-10)	10 (11, 5-19)	1.22 (0.56-2.62)	0.620
Missing	11	1		
Intermenstrual bleeding				
No	1013 (90, 88-92)	82 (92, 84-97)	1	
Yes	111 (10, 8-12)	7 (8, 3-16)	0.78 (0.35-1.77)	0.557
Missing	9	3		

Dysuria

No	978	(87, 85-89)	83	(92, 85-97)	1	
Yes	148	(13, 11-15)	7	(8, 3-15)	0.55	(0.23-1.30) 0.173
Missing	7		2			

Urinary frequency

No	935	(83, 81-85)	71	(79, 69-87)	1	
Yes	191	(17, 15-19)	19	(21, 13-31)	1.22	(0.68-2.18) 0.508
Missing	7		2			

Abbreviations: CT=*Chlamydia trachomatis*, n=number, CI=confidence interval, STI=sexually transmitted infection; m=month, VVC = vulvovaginal candidiasis

^aWomen with an unassessable CT result (n=10) or with *M. genitalium* (n= 83; includes 8 women co-infected with MG and *C. trachomatis*) were excluded from the analysis

^bAll analyses were adjusted for number of male partners, VVC, *N. gonorrhoea* and concurrent BV.

^cp-value calculated using logistic regression and bold indicates significant findings p<0.05.

^dData missing for up to 3% of participants.

^eSTI in the past six months referred to bacterial STI only, however some women may have misinterpreted this question and answered with regards to warts or other nonbacterial STI, and therefore this should be interpreted with caution.

[§] We tested for interaction terms between CT and genital co-infections and the only significant interaction was between CT and VVC for dyspareunia (p=0.016). Therefore, the association between dyspareunia and CT could not be adjusted for VVC. To account for potential confounding by VVC on the relationship between CT and dyspareunia, data were then stratified by VVC status, and the association between CT and dyspareunia was investigated within each stratum.

^fAbnormal vaginal odour refers to any self-reported odour, not specifically a fishy odour

Supplementary Table 3. Self-reported symptoms and clinical signs identified in women with <i>Mycoplasma genitalium</i> compared to women with <i>Chlamydia trachomatis</i>^{ab}					
Self-reported symptoms					
	MG positive, n=75		CT positive, n=92		p-value^c
	(%, 95% CI)		(%, 95% CI)		
Cohort					
Asymptomatic	8	(11, 5-20)	13	(14, 8-23)	0.502
Symptomatic	67	(89, 80-95)	79	(86, 77-92)	
Abdominal Pain					
No	64	(86, 77-93)	79	(86, 77-92)	0.909
Yes	10	(14, 7-23)	13	(14, 8-23)	
Missing	1		0		
Dyspareunia					
No	66	(90, 81-96)	81	(90, 82-95)	0.930
Yes	7	(10, 4-19)	9	(10, 5-18)	
Missing	2		2		
Vaginal discharge					
No	48	(65, 53-76)	48	(53, 43-64)	0.136
Yes	26	(35, 24-47)	42	(47, 36-57)	
Missing	1		2		
Abnormal odour^c					
No	60	(81, 70-89)	65	(71, 61-80)	0.150
Yes	14	(19, 11-30)	26	(29, 20-39)	
Missing	1		1		
Vaginal itch					
No	55	(74, 63-84)	77	(85, 76-91)	0.100
Yes	19	(26, 16-37)	14	(15, 9-24)	
Missing	1		1		
Post-coital bleeding					
No	64	(89, 79-95)	81	(89, 81-95)	0.980
Yes	8	(11, 5-21)	10	(11, 5-19)	
Missing	3		1		
Intermenstrual bleeding					
No	65	(88, 78-94)	82	(92, 84-97)	0.359
Yes	9	(12, 6-22)	7	(8, 3-15)	
Missing	1		3		
Dysuria					
No	64	(85, 75-92)	83	(92, 85-97)	0.158
Yes	11	(15, 8-25)	7	(8, 3-15)	
Missing	0		1		
Urinary frequency					
No	62	(83, 72-90)	71	(79, 69-88)	0.541
Yes	13	(17, 10-28)	19	(21, 13-31)	
Missing	0		2		
Fever					
No	71	(96, 89-99)	87	(97, 91-99)	0.807
Yes	3	(4, 1-11)	3	(3, 1-9)	
Missing	1		2		

Clinical signs on examination^b					
	MG positive, n=67		CT positive, n=79		p-value^c
		(%, 95% CI)		(%, 95% CI)	
Vaginal discharge					
No	15	(25, 14-37)	17	(32, 18-48)	0.826
Yes	46	(75, 63-86)	57	(68, 52-82)	
Not assessed/missing	6		5		
Abnormal odor^c					
No	44	(72, 59-83)	50	(68, 56-78)	0.566
Yes	17	(28, 14-41)	24	(32, 22-44)	
Not assessed/missing	6		5		
Vulval redness					
No	46	(75, 63-86)	61	(82, 72-90)	0.317
Yes	15	(25, 14-37)	13	(18, 10-28)	
Not assessed/missing	6		5		
Mucopurulent cervicitis					
No	37	(82, 68-92)	46	(73, 60-83)	0.263
Yes	8	(18, 8-32)	17	(27, 17-40)	
Not assessed/missing	22		16		
Cervical or adnexal motion tenderness					
No	31	(86, 71-95)	37	(76, 61-87)	0.227
Yes	5	(14, 5-29)	12	(24, 13-39)	
Not assessed/missing	31		30		
Cervical contact bleeding					
No	36	(84, 69-93)	44	(75, 62-85)	0.267
Yes	7	(16, 7-31)	15	(25, 15-38)	
Not assessed/missing	24		20		
Vaginal pH					
≤4.5	37	(56, 43-68)	38	(51, 39-63)	0.577
>4.5	29	(44, 32-57)	36	(49, 37-61)	
Not assessed/missing					
High vaginal polymorph count					
<5	35	(54, 41-66)	31	(41, 30-53)	0.121
≥5	30	(46, 34-59)	45	(59, 47-70)	
Not assessed/missing	2		3		

Notes: Abbreviations: MG=*Mycoplasma genitalium*, n=number, CI=confidence interval, CT= *Chlamydia trachomatis*

^a Analysis only includes women with CT or MG infection. Women co-infected with CT and MG have been excluded.

^b Asymptomatic women were not clinically assessed and have been excluded from the analysis. Clinical signs were elicited only in women with clinical indications for examination and in particular, cervical assessment and bimanual examination was undertaken in women with specific indications for a speculum and bimanual exam..

^c p-value calculated using Chi-square test

^c Abnormal odour refers to any odour, not specifically a fishy odour.

Indications for testing women for *M. genitalium*.

Supplementary Table 4. Associations between <i>Chlamydia trachomatis</i> and clinical signs among symptomatic women^{ab}					
	Total women n=1037	CT negative n=958 (% , 95% CI)	CT positive n=79 (% , 95% CI)	Adjusted odds ratio (95% CI)^c	p-value^d
Vaginal discharge					
No	325	308 (35, 32-39)	17 (23, 14-34)	1	
Yes	623	566 (65, 61-68)	57 (77, 66-86)	2.13 (1.19-3.82)	0.011
Not assessed/missing	89	84	5		
Abnormal odour^e					
No	717	667 (76, 73-79)	50 (68, 56-78)	1	
Yes	233	209 (24, 21-27)	24 (32, 22-44)	1.42 (0.84-2.41)	0.193
Not assessed/missing	87	82	5		
Vulval redness					
No	690	629 (72, 69-75)	61 (82, 72-90)	1	
Yes	252	239 (28, 25-31)	13 (18, 10-28)	0.82 (0.40-1.67)	0.589
Not assessed/missing	95	90	5		
Mucopurulent cervicitis					
No	657	611 (89, 86-91)	46 (73, 60-83)	1	
Yes	93	76 (11, 9-14)	17 (27, 17-40)	2.85 (1.49-5.44)	0.002
Not assessed/missing	287	271	16		
Cervical or adnexal motion tenderness					
No	482	445 (78, 75-82)	37 (76, 61-87)	1	
Yes	135	123 (22, 18-25)	12 (24, 13-39)	0.99 (0.48-2.07)	0.986
Not assessed/missing	420	390	30		
Cervical contact bleeding					
No	600	556 (86, 83-88)	44 (75, 62-85)	1	
Yes	107	92 (14, 12-17)	15 (25, 15-38)	1.93 (0.98-3.78)	0.056
Not assessed/missing	330	310	20		
Vaginal pH					
≤4.5	602	564 (62, 59-65)	38 (51, 39-63)	1	
>4.5	384	348 (38, 25-41)	36 (49, 37-61)	1.42 (0.87-2.33)	0.161
Not assessed/missing					
High vaginal polymorph count					
<5	587	556 (60, 57-63)	31 (41, 30-53)	1	
≥5	414	369 (40, 37-43)	45 (59, 47-70)	2.50 (1.49-4.20)	0.001
Not assessed/missing	36	33	3		

Abbreviations: MG=*Mycoplasma genitalium*, n=number, CI=confidence interval

^aWomen with an unassessable CT result (n=10) or with *M. genitalium* (n= 83; including 8 women coinfecting with CT and *M. genitalium* en) were excluded from the analysis. In addition, asymptomatic women (n=188) were not clinically assessed and have been excluded from the analysis.

^bClinical signs were elicited only in women with clinical indications for examination and in particular, cervical assessment and bimanual examination was undertaken in women with specific indications for a speculum and bimanual exam.

^cAll analyses were adjusted number of male sexual partners, vulvovaginal candidiasis, *N. gonorrhoea* and concurrent BV, with the exception that we did not adjust for BV in models examining associations with individual Amsel criteria (i.e. vaginal discharge, abnormal vaginal odour and vaginal pH)

^dp-value calculated using logistic regression and bold indicates significant findings p<0.05.

Indications for testing women for *M.genitalium*.

^eAbnormal vaginal odor refers to any clinician-recorded odour, not specifically a fishy odour